|18th May 2018
Precision medicine is set to revolutionise the healthcare sector, promising vastly improved outcomes for patients. However, as treatments become more precise, pharma companies will need to create more targeted commercial strategies. Meanwhile, the clinical trial recruitment process will become more challenging and a new series of stakeholders will emerge. These are just some of the barriers.
That’s why have dedicated the latest edition of our ‘Perspective’ magazine to this complex topic. We have combined the views of our in-house precision medicine experts and voices from key industry leaders to give you the latest information on the trend set to redefine healthcare as we know it – precision medicine.
In this edition of ‘Perspective’, we answer the following questions:
|3rd April 2020
Decisions made early in the drug development process can define the limits of what’s possible for products and portfolios. So, why aren’t commercial teams always involved in these early conversations? In this Q&A we deep dive into early stage strategy, including how to break down these siloes and rethink drug development and clinical trial design.
|27th March 2020
Senior Associate Consultant, Manos Mastorakis, takes a look at a number of COVID-19 drugs that are already registered in clinical trials, providing analysis aiming to simplify the current landscape.
|6th March 2020
BLH speaks to MM patient advocate, Peter McCleave, to find out how he has fought to remain positive throughout his treatment journey while simultaneously leading a successful campaign to get more people to sign up to be a blood stem cell donor.